These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2567345)

  • 1. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
    Braun A; Mouradian MM; Mohr E; Fabbrini G; Chase TN
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):631-5. PubMed ID: 2567345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders.
    Mondrup K; Dupont E; Braendgaard H
    Acta Neurol Scand; 1985 Sep; 72(3):341-3. PubMed ID: 3864333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dopamine antagonists in spontaneous and tardive dyskinesia.
    Fog R
    Psychopharmacology Suppl; 1985; 2():118-21. PubMed ID: 2860655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
    Fabbrini G; Braun A; Mouradian MM; Tamminga CA; Chase TN
    J Neural Transm; 1988; 71(3):159-63. PubMed ID: 2965754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
    Braun A; Fabbrini G; Mouradian MM; Serrati C; Barone P; Chase TN
    J Neural Transm; 1987; 68(1-2):41-50. PubMed ID: 2949059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trial use of clozapine for abnormal involuntary movement disorders.
    Caine ED; Polinsky RJ; Kartzinel R; Ebert MH
    Am J Psychiatry; 1979 Mar; 136(3):317-20. PubMed ID: 154301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.
    Goetz CG; Stebbins GT; Thelen JA
    Mov Disord; 1994 May; 9(3):315-7. PubMed ID: 7913738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are D1 dopamine receptor agonists potential antidepressants?
    Serra G; Collu M; D'Aquila P; Pani L; Gessa GL
    Pharmacol Res Commun; 1988 Dec; 20(12):1121-2. PubMed ID: 2905479
    [No Abstract]   [Full Text] [Related]  

  • 10. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.
    Quinn N; Marsden CD
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):844-7. PubMed ID: 6236286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatments: replacement therapy with choline or lecithin in neurological diseases.
    Barbeau A
    Can J Neurol Sci; 1978 Feb; 5(1):157-60. PubMed ID: 148319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbamazepine-induced tics.
    Kurlan R; Kersun J; Behr J; Leibovici A; Tariot P; Lichter D; Shoulson I
    Clin Neuropharmacol; 1989 Aug; 12(4):298-302. PubMed ID: 2529963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-1 and D-2 receptor manipulation in Cebus monkeys: implication for extrapyramidal syndromes in humans.
    Gerlach J; Casey D; Kistrup K
    Clin Neuropharmacol; 1986; 9 Suppl 4():131-3. PubMed ID: 2952267
    [No Abstract]   [Full Text] [Related]  

  • 15. The Simon effect and attention deficits in Gilles de la Tourette's syndrome and Huntington's disease.
    Georgiou N; Bradshaw JL; Phillips JG; Bradshaw JA; Chiu E
    Brain; 1995 Oct; 118 ( Pt 5)():1305-18. PubMed ID: 7496788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lithium carbonate in the treatment of movement disorders. A critical review.
    Yassa R; Ananth J
    Int Pharmacopsychiatry; 1980; 15(5):301-8. PubMed ID: 6114936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histamine H3 receptor agonist- and antagonist-evoked vacuous chewing movements in 6-OHDA-lesioned rats occurs in an absence of change in microdialysate dopamine levels.
    Nowak P; Dabrowska J; Bortel A; Biedka I; Szczerbak G; Słomian G; Kostrzewa RM; Brus R
    Eur J Pharmacol; 2006 Dec; 552(1-3):46-54. PubMed ID: 17055481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet dopamine uptake in Huntington's chorea and Gilles de la Tourette's syndrome: effect of haloperidol.
    Butterworth RF; Gonce M; Barbeau A
    Can J Neurol Sci; 1977 Nov; 4(4):285-8. PubMed ID: 145893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients.
    Barone P; Braun AR; Chase TN
    Clin Neuropharmacol; 1986; 9 Suppl 4():128-30. PubMed ID: 2952266
    [No Abstract]   [Full Text] [Related]  

  • 20. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.